{"title":"Management of dupilumab-related ocular surface disorders.","authors":"Tina Felfeli, Aaron M Drucker","doi":"10.1093/bjd/ljae350","DOIUrl":"10.1093/bjd/ljae350","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":"857-858"},"PeriodicalIF":3.5,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142124873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Junxian Wen, Yingrou Tan, Yong Yao Chun, Timothy T Y Tan, Hong Liang Tey
{"title":"Crosstalk Between Fibroblasts and Immune Cells in keloids.","authors":"Junxian Wen, Yingrou Tan, Yong Yao Chun, Timothy T Y Tan, Hong Liang Tey","doi":"10.1093/bjd/ljae449","DOIUrl":"https://doi.org/10.1093/bjd/ljae449","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
John T Lear, Catherine A Harwood, Zeeshaan Hasan, Jonathan Kentley, Jason Thomson, Andre Khoo, Alix Alderman, Mark DeSouza, Ervin H Epstein, Gerd G Kochendoerfer, Jean Y Tang
Background: Patients with Gorlin (basal cell nevus) syndrome (GS) have numerous phenotypic abnormalities due to over-activity of the hedgehog (HH) signaling pathway, most commonly due to a heritable mutation in the PTCH1 gene, which encodes a major inhibitor of this pathway. HH inhibitors (HHi) taken orally can reverse some of the manifestations, most prominent of which is the development of numerous cutaneous basal cell carcinomas (BCCs). In order to improve the benefit:risk ratio, we have developed a gel containing a small cyclopamine-derived molecule that can be applied topically in expectation that this mode of delivery can reduce the burden of BCCs without producing the systemic adverse effects that cause patients to stop treatment with oral HHis.
Objectives: This study attempts to determine whether or not Patidegib Topical Gel, 2% or 4%, can accumulate in high enough concentrations to have local anti-BCC efficacy but not so high that systemic drug levels produce the adverse effects that are typical of oral HHi treatment.
Methods: We conducted a small, randomized, double blinded Phase 2A trial at two sites in the United Kingdom to assess the clinical and molecular efficacy and adverse effects of 6 months of twice daily application of Patidegib Topical Gel to the entire face as well as to treatment-targeted surgically-eligible BCCs at other anatomical sites.
Results: Post hoc analyses suggested that Patidegib Topical Gel reduced the number of new surgically-eligible BCCs and the level of HH signaling with minimal adverse effects.
Conclusions: Patidegib Topical Gel warrants further clinical development.
{"title":"Phase 2 Trial of Topical Application of the Hedgehog Inhibitor Patidegib in Patients With Gorlin Syndrome.","authors":"John T Lear, Catherine A Harwood, Zeeshaan Hasan, Jonathan Kentley, Jason Thomson, Andre Khoo, Alix Alderman, Mark DeSouza, Ervin H Epstein, Gerd G Kochendoerfer, Jean Y Tang","doi":"10.1093/bjd/ljae444","DOIUrl":"https://doi.org/10.1093/bjd/ljae444","url":null,"abstract":"<p><strong>Background: </strong>Patients with Gorlin (basal cell nevus) syndrome (GS) have numerous phenotypic abnormalities due to over-activity of the hedgehog (HH) signaling pathway, most commonly due to a heritable mutation in the PTCH1 gene, which encodes a major inhibitor of this pathway. HH inhibitors (HHi) taken orally can reverse some of the manifestations, most prominent of which is the development of numerous cutaneous basal cell carcinomas (BCCs). In order to improve the benefit:risk ratio, we have developed a gel containing a small cyclopamine-derived molecule that can be applied topically in expectation that this mode of delivery can reduce the burden of BCCs without producing the systemic adverse effects that cause patients to stop treatment with oral HHis.</p><p><strong>Objectives: </strong>This study attempts to determine whether or not Patidegib Topical Gel, 2% or 4%, can accumulate in high enough concentrations to have local anti-BCC efficacy but not so high that systemic drug levels produce the adverse effects that are typical of oral HHi treatment.</p><p><strong>Methods: </strong>We conducted a small, randomized, double blinded Phase 2A trial at two sites in the United Kingdom to assess the clinical and molecular efficacy and adverse effects of 6 months of twice daily application of Patidegib Topical Gel to the entire face as well as to treatment-targeted surgically-eligible BCCs at other anatomical sites.</p><p><strong>Results: </strong>Post hoc analyses suggested that Patidegib Topical Gel reduced the number of new surgically-eligible BCCs and the level of HH signaling with minimal adverse effects.</p><p><strong>Conclusions: </strong>Patidegib Topical Gel warrants further clinical development.</p>","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Interactive effect of genetic and environmental risk factors on Psoriasis: current evidence and future directives.","authors":"Nidhi Singh, Tamara Schikowski","doi":"10.1093/bjd/ljae450","DOIUrl":"https://doi.org/10.1093/bjd/ljae450","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Real-world data confirms limited efficacy of dual anti-PD-1 and CTLA-4 immune checkpoint blockade in acral lentiginous melanoma.","authors":"David X Zheng, Russell W Jenkins","doi":"10.1093/bjd/ljae445","DOIUrl":"https://doi.org/10.1093/bjd/ljae445","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Robert Gniadecki, Emmanuella Guenova, Christiane Querfeld, Jan P Nicolay, Julia Scarisbrick, Lubomir Sokol
Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of diseases characterised by abnormal neoplastic T-cell growth in the skin. Mycosis fungoides (MF), the most common CTCL, manifests as erythematous skin patches and/or plaques, tumours or erythroderma. The disease may involve blood, lymph nodes and rarely viscera. Sézary syndrome (SS) is a unique leukaemia/lymphoma syndrome related to MF, which presents with blood and skin involvement at diagnosis. The pathogenesis of MF/SS is not fully elucidated. The presence of skin lesions at distant sites underpins a hypothesis that MF/SS lesions may develop through haematogenous seeding. Phenotypic similarities between malignant and normal T-cells led to the notion that disease-initiating mutations occur in specific subtypes of mature T-cells, which are responsible for most CTCLs. However, this mature T-cell precursor model is not always consistent with clinical observations and research on MF/SS pathogenesis. Here, we review evidence supporting an alternative model of pathogenesis for MF/SS involving haematogenous seeding as a key process responsible for the initiation and progression of the disease. According to this hypothesis, malignant transformation occurs at an early stage of T-cell development (probably in bone marrow or thymus), yielding circulating neoplastic T-cells which colonise the skin where the microenvironment is most permissive for proliferation and evolution. These mutated precursor cells seed the skin where they find a suitable niche to develop into clinically perceptible disease. Subsequently, malignant T-cells can re-enter the bloodstream, re-seed pre-existing lesions and seed new areas of the skin, causing synchronous and convergent changes in the transcriptomic profile of lesions and tumours, and clinical disease progression - 'consecutive haematogenous seeding' captures this temporal phenomenon. This model radically changes the current understanding of CTCL pathogenesis, transforming it from a primarily cutaneous disease with secondary involvement of blood, to a systemic disease, where the spread of malignant cells through the blood to the skin is not a phenomenon of advanced disease but is an essential component of pathogenesis. This understanding of MF/SS could have several clinical implications, including standardising our approach to assessing blood tumour burden, potential advances in prognosis and monitoring, and investigating combination treatments to improve patient outcomes.
皮肤 T 细胞淋巴瘤(CTCLs)是一类异质性疾病,其特征是皮肤中出现异常的肿瘤性 T 细胞生长。放线菌病(MF)是最常见的皮肤 T 细胞淋巴瘤,表现为皮肤红斑和/或斑块、肿瘤或红斑。该病可累及血液、淋巴结,很少累及内脏。塞扎里综合征(SS)是与 MF 相关的一种独特的白血病/淋巴瘤综合征,确诊时表现为血液和皮肤受累。MF/SS 的发病机制尚未完全阐明。远处皮肤病变的出现支持了一种假设,即 MF/SS 病变可能是通过血源性播种形成的。恶性 T 细胞和正常 T 细胞在表型上的相似性使人们认为,疾病的诱发突变发生在特定亚型的成熟 T 细胞中,它们是大多数 CTCL 的罪魁祸首。然而,这种成熟 T 细胞前体模型并不总是与 MF/SS 发病机制的临床观察和研究相一致。在此,我们回顾了支持 MF/SS 发病机制替代模型的证据,该模型将血源性播种作为疾病发生和发展的关键过程。根据这一假说,恶性转化发生在 T 细胞发育的早期阶段(可能在骨髓或胸腺中),产生循环肿瘤性 T 细胞,这些细胞在微环境最有利于增殖和进化的皮肤上定植。这些变异的前体细胞在皮肤上播种,并在那里找到合适的生长环境,发展成临床上可感知的疾病。随后,恶性 T 细胞会再次进入血液,重新播种已有的病灶,并播种新的皮肤区域,导致病灶和肿瘤的转录组发生同步和趋同的变化,并导致临床疾病进展--"连续血源性播种 "捕捉到了这一时间现象。这一模型从根本上改变了目前对 CTCL 发病机制的认识,将其从一种主要是皮肤病、继发于血液的疾病转变为一种全身性疾病,在这种疾病中,恶性细胞通过血液扩散到皮肤并不是疾病晚期的一种现象,而是发病机制的一个重要组成部分。对 MF/SS 的这种认识可能会产生一些临床影响,包括使我们评估血液肿瘤负荷的方法标准化、预后和监测方面的潜在进步以及研究改善患者预后的综合治疗方法。
{"title":"Haematogenous seeding in mycosis fungoides and Sézary syndrome: Current evidence and clinical implications.","authors":"Robert Gniadecki, Emmanuella Guenova, Christiane Querfeld, Jan P Nicolay, Julia Scarisbrick, Lubomir Sokol","doi":"10.1093/bjd/ljae441","DOIUrl":"https://doi.org/10.1093/bjd/ljae441","url":null,"abstract":"<p><p>Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of diseases characterised by abnormal neoplastic T-cell growth in the skin. Mycosis fungoides (MF), the most common CTCL, manifests as erythematous skin patches and/or plaques, tumours or erythroderma. The disease may involve blood, lymph nodes and rarely viscera. Sézary syndrome (SS) is a unique leukaemia/lymphoma syndrome related to MF, which presents with blood and skin involvement at diagnosis. The pathogenesis of MF/SS is not fully elucidated. The presence of skin lesions at distant sites underpins a hypothesis that MF/SS lesions may develop through haematogenous seeding. Phenotypic similarities between malignant and normal T-cells led to the notion that disease-initiating mutations occur in specific subtypes of mature T-cells, which are responsible for most CTCLs. However, this mature T-cell precursor model is not always consistent with clinical observations and research on MF/SS pathogenesis. Here, we review evidence supporting an alternative model of pathogenesis for MF/SS involving haematogenous seeding as a key process responsible for the initiation and progression of the disease. According to this hypothesis, malignant transformation occurs at an early stage of T-cell development (probably in bone marrow or thymus), yielding circulating neoplastic T-cells which colonise the skin where the microenvironment is most permissive for proliferation and evolution. These mutated precursor cells seed the skin where they find a suitable niche to develop into clinically perceptible disease. Subsequently, malignant T-cells can re-enter the bloodstream, re-seed pre-existing lesions and seed new areas of the skin, causing synchronous and convergent changes in the transcriptomic profile of lesions and tumours, and clinical disease progression - 'consecutive haematogenous seeding' captures this temporal phenomenon. This model radically changes the current understanding of CTCL pathogenesis, transforming it from a primarily cutaneous disease with secondary involvement of blood, to a systemic disease, where the spread of malignant cells through the blood to the skin is not a phenomenon of advanced disease but is an essential component of pathogenesis. This understanding of MF/SS could have several clinical implications, including standardising our approach to assessing blood tumour burden, potential advances in prognosis and monitoring, and investigating combination treatments to improve patient outcomes.</p>","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Morvarid Zehtab, L Claire Fuller, Wendemagegn Enbiale, Karolyn A Wanat, Luca Borradori, Henry W Lim, Esther E Freeman
{"title":"Emerging Challenges in Global Health Dermatology: measuring impact and sustainability.","authors":"Morvarid Zehtab, L Claire Fuller, Wendemagegn Enbiale, Karolyn A Wanat, Luca Borradori, Henry W Lim, Esther E Freeman","doi":"10.1093/bjd/ljae435","DOIUrl":"https://doi.org/10.1093/bjd/ljae435","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mark J Arends, Martin Del Castillo Velasco-Herrera, Saamin Cheema, Kim Wong, Jacqueline M Boccacino, Ian Vermes, Kirsty Roberts, Elizabeth Anderson, Michiel P J van der Horst, Nicolas de Saint Aubain, Ahmed K Alomari, Carlos Monteagudo, Steven D Billings, Derek Frew, Emily Clarke, William Merchant, Neil Rajan, Peter Ferguson, Carolin Mogler, Ingrid Ferreira, Thomas Brenn, Louise van der Weyden, David J Adams
{"title":"Exploring the driver events of eccrine poromas and porocarcinomas: A retrospective, cross-institutional study of 54 cases.","authors":"Mark J Arends, Martin Del Castillo Velasco-Herrera, Saamin Cheema, Kim Wong, Jacqueline M Boccacino, Ian Vermes, Kirsty Roberts, Elizabeth Anderson, Michiel P J van der Horst, Nicolas de Saint Aubain, Ahmed K Alomari, Carlos Monteagudo, Steven D Billings, Derek Frew, Emily Clarke, William Merchant, Neil Rajan, Peter Ferguson, Carolin Mogler, Ingrid Ferreira, Thomas Brenn, Louise van der Weyden, David J Adams","doi":"10.1093/bjd/ljae447","DOIUrl":"https://doi.org/10.1093/bjd/ljae447","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}